MedTrace Logo

Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients

NCT04472585 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-02-17

No results posted yet for this study

Summary

To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

Conditions

  • Coronavirus Infection
  • COVID
  • Sars-CoV2

Interventions

DRUG

Ivermectin Injectable Solution

Subcutaneous Ivermectin 200ug/kg body weight 48 hourly

OTHER

Injectable Placebo

0.9% normal saline

DRUG

Zinc

Zinc Sulphate 20mg 3 times a day

DRUG

Placebo empty capsule

Placebo empty capsule

DRUG

Oral Ivermectin

0.2mg/kg/day

Sponsors & Collaborators

  • Sohaib Ashraf

    lead OTHER

Principal Investigators

  • Muhammad Ashraf, PhD · University of Veterinary & Animal Sciences, Lahore, Pakistan

  • Shoaib Ashraf, PhD · Harvard University Boston, USA

  • Sohaib Ashraf, MBBS · Shaikh Zayed Medical Complex, Pakistan

  • Moneeb Ashraf, MBBS · Mayo Hospital, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-14
Primary Completion
2021-08-15
Completion
2021-10-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04472585 on ClinicalTrials.gov